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Data on nontuberculous mycobacterial (NTM) disease 
in sub-Saharan Africa are limited. During 2006–2008, we 
identiﬁ  ed 3 HIV-infected patients in northern Tanzania who 
had invasive NTM; 2 were infected with “Mycobacterium 
sherrisii” and 1 with M. avium complex sequevar MAC-D. 
Invasive NTM disease is present in HIV-infected patients in 
sub-Saharan Africa.
I
n sub-Saharan Africa, mycobacterial infections are pre-
dominantly caused by Mycobacterium tuberculosis (1). 
In more developed countries, M. avium and M. simiae are 
responsible for disseminated disease in HIV-infected per-
sons (2). To better understand invasive nontuberculous my-
cobacterial (NTM) infections in HIV-infected persons in 
sub-Saharan Africa, we studied patients at 2 hospitals in 
northern Tanzania.
The Study
From July 2006 through August 2008, we collected 
blood from 723 patients >13 years of age who had axillary 
temperatures >38ºC and who had been admitted to Kili-
manjaro Christian Medical Centre and Mawenzi Regional 
Hospital in Moshi, Tanzania. Standardized clinical infor-
mation was collected from all patients. For mycobacterial 
culture, 5 mL from each patient was inoculated into a BacT/
ALERT MB bottle and monitored in a BacT/ALERT 3D 
(bioMérieux, Durham, NC, USA) automated liquid culture 
instrument. Other tissue samples (not blood) were obtained 
from patients with suspected invasive mycobacterial dis-
ease and incubated on Middlebrook 7H10 and Lowenstein-
Jensen media at 36°C. We used AccuProbe MTB and MAC 
kits (GenProbe, San Diego, CA, USA) to identify members 
of M. tuberculosis complex and M. avium complex. NTM 
were further identiﬁ  ed by INNO-LiPA Mycobacteria v2 
reverse line blot (Innogenetics, Gent, Belgium). All assays 
were used according to the manufacturer’s instructions. All 
reverse line blot identiﬁ  cations were conﬁ  rmed by perform-
ing additional sequencing of the complete 16S rDNA gene, 
the 16S–23S internal transcribed spacer (ITS), and the heat 
shock protein 65 (hsp65) gene (3,4).
Of the 723 patients, 30 (4.1%) had mycobacterial 
bloodstream infections, of which 2 (9%) were NTM. In 1 
additional patient, NTM was identiﬁ  ed in a tissue speci-
men. We describe the 3 patients with NTM infections.
The ﬁ  rst patient was a 49-year-old man with cough and 
weight loss. His sputum contained acid-fast bacilli, and he 
simultaneously received a diagnosis of HIV infection with 
a CD4-positive T-lymphocyte count (CD4 count) of 9 cells/
mm3. Tuberculosis therapy was begun and comprised isoni-
azid, rifampin, pyrazinamide, and ethambutol; he was also 
started on a ﬁ  xed-dose combination of zidovudine, lami-
vudine, and abacavir. DNA was extracted from the initial 
sputum smear taken at the time of presumptive tuberculosis 
diagnosis according to previously published methods (5). 
The GenoType CM/AS reverse line blot assay (Hain Life-
sciences, Nehren, Germany) was weakly positive for M. tu-
berculosis complex. The patient’s cough resolved, and he 
completed a 9-month course of tuberculosis therapy. When 
fever subsequently developed, he was admitted to the hos-
pital; CD4 count was 13 cells/mm3. Mycobacterial blood 
culture grew acid-fast bacilli after 12 days of incubation; 
results of AccuProbe MTB and MAC tests were negative. 
Heat-killed cells from the positive blood culture were iden-
tiﬁ  ed as M. simiae by the INNO-LiPA reverse-line blot. Se-
quencing of the full 16S rDNA gene, ITS, and hsp65 gene 
identiﬁ  ed the isolate as “M. sherrisii.” The 16S rDNA and 
hsp65 sequences were identical to the M. sherrisii Ameri-
can Type Culture Collection (ATCC; Manassas, VA, USA) 
BAA-832 strain sequences deposited in the GenBank se-
quence database under accession nos. AY353699 (16S 
rDNA) and AY365190 (hsp65). The ITS sequence was 
identical to that of M. sherrisii strain FI-95229 (accession 
no. DQ185132), isolated from sputum of a patient in Italy 
(6). The Tanzania patient was treated with azithromycin, 
500 mg/day, and ethambutol, 800 mg/day. His fever abated 
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The second patient was a 36-year-old HIV-infected 
man with a 3-month history of fever and weight loss and 31 
CD4 cells/mm3. He had been taking ﬁ  xed-dose combina-
tion stavudine, lamivudine, and nevirapine for 5 months, 
but his adherence to therapy was poor. A mycobacterial 
blood culture grew acid-fast bacilli after 15 days of incuba-
tion; AccuProbe MTB and MAC test results were negative. 
Heat-killed cells from the positive blood culture were iden-
tiﬁ  ed as M. simiae by the INNO-LiPA reverse-line blot and 
again as M. sherrisii by sequencing of the full 16S rDNA 
gene, ITS, and the hsp65 gene. The 16S rDNA gene had 
a single base-pair difference when compared with the M. 
sherrisii ATCC BAA-832 strain sequence in GenBank. We 
deposited the new 16S rDNA sequence in GenBank under 
accession no. EU883389. The hsp65 sequence was identi-
cal to the M. sherrisii ATCC BAA-832 strain sequence (ac-
cession no. AY365190); the ITS sequence was identical to 
the M. sherrisii strain FI-95229 (accession no. DQ185132) 
sequence (6). The patient was treated with azithromycin, 
500 mg/day, and ethambutol, 800 mg/day; fever abated. 
At follow-up in 2008, the patient was continuing treat-
ment with azithromycin and ethambutol but had abdominal 
pain and hepatosplenomegaly. Abdominal ultrasonography 
showed retroperitoneal lymphadenopathy. Follow-up my-
cobacterial blood cultures have been negative.
The third patient was a 36-year-old HIV-infected 
woman with a 4-month history of bilateral skin lesions af-
fecting the lower extremities (Figure) and 206 CD4 cells/
mm3. HIV infection had been diagnosed 18 months earlier; 
baseline CD4 count was 6 cells/mm3. She began ﬁ  xed-dose 
combination stavudine, lamivudine, and nevirapine soon 
after her HIV diagnosis. An incisional biopsy from the ac-
tive margin of a leg lesion showed several foci of dermal 
necrosis with dense lymphocytic inﬁ  ltrate and Langhans-
type giant cells consistent with granulomatous inﬂ  amma-
tion of tuberculosis (Figure). Culture of biopsy material 
was positive for M. avium complex. The isolate reacted 
only with the M. avium-intracellulare-scrofulaceum com-
plex probe of the INNO-LiPA reverse-line blot. The 16S 
rDNA gene and ITS sequences were identical to the M. 
avium complex ATCC 35770 (Melnick) strain sequences 
published by Böddinghaus et al. (7) and available in the 
Ribosomal Differentiation of Microorganisms database 
(http://rdna.ridom.de). The ITS sequence was also identical 
to the MAC ATCC 35770 strain sequence available in Gen-
Bank (ITS sequevar MAC-D, accession no. L07851). The 
hsp65 sequence was identical to the ATCC 35770 sequence 
(accession no. U85637). Because the full 16S rDNA gene 
sequence of this strain was not available in GenBank and 
only a small fragment of hsp65 was available, we depos-
ited our sequences under accession nos. EU815938 (16S 
rDNA) and EU935586 (hsp65). This patient was treated 
with azithromycin, 500 mg/day, ethambutol, 800 mg/day, 
and rifampin, 600 mg/day. Her lesions abated over the sub-
sequent weeks, and she remained well as of follow-up in 
2008.
Conclusions
Improved laboratory techniques enabled us to dem-
onstrate that invasive NTM infections occur in northern 
Tanzania and include M. sherrisii and M. avium complex. 
M. sherrisii still awaits ofﬁ  cial recognition (8). Of M. 
sherrisii infections reported to date (6,9–12), most have 
been in HIV-infected patients from Africa (9–11). Al-
though recommendations for the antimicrobial drug man-
agement of these infections have not yet been established, 
our 2 patients with M. sherrisii disseminated disease re-
sponded clinically to the optimization of their antiretrovi-
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Figure. A 36-year-old HIV-infected woman with Mycobacterium 
avium disease. A) Photograph of skin lesions on right leg, taken 
before treatment. B) Histopathologic appearance of skin biopsy 
specimen from right leg lesion (stain, hematoxylin and eosin; 
magniﬁ  cation ×40).Invasive Nontuberculous Mycobacteria, Tanzania
ral therapy regimen and to the combination of ethambutol 
and azithromycin.
The M. avium complex isolated from our third patient 
is remarkable for its ITS sequevar type. MAC-D has not 
previously been associated with invasive disease in HIV-
infected patients, in which M. avium sequevars, mainly 
Mav-A and -B, are most common (13). The M. avium com-
plex ATCC 35770 reference strain was the ﬁ  rst reported 
strain with a MAC-D ITS. The ATCC 35770 strain, how-
ever, was isolated from a sputum sample in a symptomatic 
patient in the United States (14). The isolate from our third 
patient and the ATCC 35770 strain are genetically diver-
gent from other M. avium complex members and may rep-
resent a separate species within the M. avium complex.
Invasive NTM disease in HIV-infected populations 
in sub-Saharan Africa demands more attention in terms of 
identiﬁ  cation of etiologic agents, clinical relevance, and 
management. Further insights would be gained if current 
and future studies on tuberculosis in the region included 
liquid culture and molecular identiﬁ  cation to conﬁ  rm M. 
tuberculosis infection and establish the epidemiology and 
clinical relevance of NTM. 
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